Scholarlink

<p>Chemotherapy-induced immunosuppression compromises therapeutic outcomes in oncology, particularly in non-small cell lung cancer (NSCLC). While natural polysaccharides have emerged as promising candidates to counteract drug-related immunosuppression, the therapeutic potential of riclin remains unexplored in chemotherapeutic contexts. Here, we systematically evaluated riclin’s immunoadjuvant efficacy in a murine NSCLC model treated with gemcitabine (GEM). Oral riclin modulated gut microbiota diversity and metabolite profiles while activating the immune-hematopoietic axis, thereby boosting immunity and hematopoiesis. Mechanistically, riclin counteracted GEM-induced immunosuppression through coordinated NF-κB and JAK-STAT activation, as evidenced by the restoration of circulating immune cells and splenic architecture, expansion of bone marrow mononuclear cells (BMNCs) and Lineage⁻Sca-1⁺Kit⁺ (LSK) cells, and suppression of apoptosis. Notably, riclin demonstrated synergistic effects with GEM, achieving 98% tumor burden reduction while concurrently alleviating systemic immunosuppression. We propose that riclin, a novel oral immunoadjuvant capable of enhancing chemotherapeutic efficacy in NSCLC, supports its clinical development as a promising combination strategy.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Natural polysaccharide riclin acts as an immune adjuvant to enhance chemotherapy efficacy in NSCLC

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月4日

查看全文
  • Yaqiong Miao,
  • Xiaofen Liu,
  • Jing Tao,
  • Yang Jiao,
  • Yizhuo Fan,
  • Xiaqing Sun,
  • Junhao Liu,
  • Zhao Ding,
  • Jianfa Zhang,
  • Qin Gao,
  • Qi Sun

摘要

Chemotherapy-induced immunosuppression compromises therapeutic outcomes in oncology, particularly in non-small cell lung cancer (NSCLC). While natural polysaccharides have emerged as promising candidates to counteract drug-related immunosuppression, the therapeutic potential of riclin remains unexplored in chemotherapeutic contexts. Here, we systematically evaluated riclin’s immunoadjuvant efficacy in a murine NSCLC model treated with gemcitabine (GEM). Oral riclin modulated gut microbiota diversity and metabolite profiles while activating the immune-hematopoietic axis, thereby boosting immunity and hematopoiesis. Mechanistically, riclin counteracted GEM-induced immunosuppression through coordinated NF-κB and JAK-STAT activation, as evidenced by the restoration of circulating immune cells and splenic architecture, expansion of bone marrow mononuclear cells (BMNCs) and Lineage⁻Sca-1⁺Kit⁺ (LSK) cells, and suppression of apoptosis. Notably, riclin demonstrated synergistic effects with GEM, achieving 98% tumor burden reduction while concurrently alleviating systemic immunosuppression. We propose that riclin, a novel oral immunoadjuvant capable of enhancing chemotherapeutic efficacy in NSCLC, supports its clinical development as a promising combination strategy.